ACSL4 and hepatocellular carcinoma: Notably, growing evidence pinpointed that ACSL4 can serve as a potential prognostic factor for overall survival and disease-free survival time [101, 102], suggesting that ACSL4 might be a therapeutic target for HCC patients, especially for those at an advanced stage posttreatment with sorafenib.